Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Off-the-shelf NK Cells + SCT for Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating off-the-shelf natural killer (NK) cells in combination with stem cell transplantation for myeloid malignancies has …
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia [Phase 1, Phase 2]
Clinical trial update for 211At-BC8-B10 given before donor stem cell transplant in high-risk acute myeloid leukemia, acute lymphoblastic leu…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Cladribine Venetoclax in Monocytic AML [Phase 2]
A Phase 2 clinical trial evaluating the combination of cladribine and venetoclax for monocytic acute myeloid leukemia, currently recruiting.
-
CLINICAL_TRIALS other · 2025-12-19Clinical Trial Update: Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia [Phase 1]
A Phase 1 clinical trial evaluating pemigatinib after chemotherapy for newly diagnosed acute myeloid leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies [Phase 1, Phase 2]
A Phase 1/2 study is evaluating CCS1477 (Inobrodib) in multiple hematologic malignancies and is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-12-18EMA Authorised: Azacitidine Kabi (azacitidine) — Fresenius Kabi Deutschland GmbH
EMA authorised Azacitidine Kabi (azacitidine) from Fresenius Kabi Deutschland GmbH for use in the EU. The product is indicated for myelodysp…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating cytokine-treated veto cells as an adoptive therapy after stem cell transplantation for various hematolog…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial at MD Anderson is evaluating a quadruplet regimen of cladribine, idarubicin, cytarabine, and quizartinib for newl…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia [Phase 1, Phase 2]
A biomarker-based treatment approach for acute myeloid leukemia is being studied in Phase 1/2 trials and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Safety of MT-401-OTS in Patients With Relapsed AML or MDS [Phase 1]
A Phase 1 clinical trial update assessing the safety of MT-401-OTS in patients with relapsed acute myeloid leukemia or myelodysplastic syndr…
-
CLINICAL_TRIALS trial_result · 2025-12-16Clinical Trial Update: Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven [NA]
This clinical trial update reports on the plasma dosing of venetoclax in AML patients treated with azacitidine plus venetoclax. The study st…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia
An update on a clinical trial evaluating natural killer cell therapy for monitoring patients with acute myeloid leukemia, acute lymphoblasti…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) [Phase 1]
Phase 1 study of a CD70-targeted chimeric antigen receptor (CAR) T-cell therapy named SEVENTY for acute leukemias; the trial is not yet recr…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Home Blood Transfusions [NA]
Thomas Jefferson University is recruiting for a clinical trial on home blood transfusions. The study targets patients with hematologic malig…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia [Phase 1]
A Phase I pediatric trial evaluating the combination of the menin inhibitor ziftomenib with venetoclax and gemtuzumab ozogamicin in acute my…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a combination of sorafenib, busulfan, and fludarabine as conditioning therapy for patients with recurr…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1, Phase 2]
The first-in-human study of SAR443579 in children and adults with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemi…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
This clinical trial study characterizes the T-cell repertoire in patients with acute myeloid leukemia undergoing donor stem cell transplant …
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating SupCD7 CAR T-cell therapy for relapsed or refractory CD7-positive hematologic malignancies is cu…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Clinical trial sponsored by the National Cancer Institute studying individuals and families with DDX41 or similar cancer predisposition vari…
-
EMA approval · 2025-12-12EMA Authorised: Azacitidine Mylan (azacitidine) — Mylan Pharmaceuticals Limited
EU authorisation granted for Azacitidine Mylan for treatment of myelodysplastic syndromes and certain leukemias, expanding access to azaciti…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy [Phase 2]
Phase 2 trial evaluating the combination of sirolimus and azacitidine in adults with high-risk myelodysplastic syndrome or acute myeloid leu…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
Completed clinical trial assessing change in disease state in adults with Acute Myeloid Leukemia ineligible for intensive chemotherapy, eval…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS [Phase 1, Phase 2]
This document reports an ongoing Phase 1/Phase 2 clinical trial of ARD103 CAR-T therapy for relapsed/refractory acute myeloid leukemia and m…
-
EMA approval · 2025-12-09EMA Authorised: Dacogen (decitabine) — Janssen-Cilag International N.V.
The EMA authorised Dacogen (decitabine) for use in myeloid leukemias, including myelodysplastic syndromes and acute myeloid leukemia.